Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 8—August 2020
Research

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France

Marie JaspardComments to Author , Nathalie Butel, Najoua El Helali, Dhiba Marigot-Outtandy, Helene Guillot, Gilles Peytavin, Nicolas Veziris, Bahram Bodaghi, Philippe Flandre, Gregoire Petitjean, Eric Caumes, and Valerie Pourcher
Author affiliations: Sorbonne Université, Paris, France (M. Jaspard, H. Guillot, N. Veziris, B. Bodaghi, E. Caumes, V. Pourcher); Assistance Publique–Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Paris (M. Jaspard, H. Guillot, E. Caumes, V. Pourcher); Assistance Publique – Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris (N. Butel, B. Bodaghi); Groupe Hospitalier Paris Saint Joseph, Paris (N. El Helali, G. Petitjean); Bligny Medical Center, Briis sous Forges, France (D. Marigot-Outtandy); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris (G. Peytavin); Université Paris Diderot, Sorbonne Paris Cité, Paris (G. Peytavin); Assistance Publique–Hôpitaux de Paris, Hôpitaux Universitaires de l’Est Parisien, Paris (N. Veziris); Institut Pierre Louis Institute d’Épidémiologie et de Santé Publique, Paris (P. Flandre, E. Caumes, V. Pourcher)

Main Article

Table 5

Association between clinical and confirmed peripheral and optical neuropathy and patient characteristics among 57 patients with multidrug-resistant tuberculosis, Pitié-Salpêtrière Hospital, Paris, France, 2011–2016*

Characteristic Clinical neuropathy
 Confirmed neuropathy
Value p value* Value p value*
Age, OR (95% CI)† 1.83 (0.9–3.7) 0.09 1.66 (0.8–3.3) 0.14
Immunosuppression treatment, OR (95% CI) 0.91 (0.3–2.7) 0.98 2.1 (0.7–6.2) 0.18
History of intravenous drug use, OR (95% CI) 0.43 (0.5–4.9) 0.43 1.79 (0.6–5.4) 0.30
Opioid substitution therapy, OR (95% CI) 1.6 (0.4–6.1) 0.49 1.92 (0.5–7) 0.32
Albumin, g/L 0.81 (0.4–1.8) 0.61 1.01 (0.5–2.2) 0.98
Linezolid treatment duration, mo 0.47 (0.2–1.2) 0.10 1.11 (0.5–2.7) 0.82
Culture conversion, d 0.93 (0.8–1.1) 0.35 1.15 (0.9–1.4) 0.21
Trough linezolid concentration >2 mg/L 2.07 (0.6–7.3) 0.26 0.83 (0.3–2.7) 0.76

*p values from univariate logistic models. OR, odds ratio.
†Risk based on age increase by 10-y intervals.

Main Article

Page created: June 12, 2020
Page updated: July 17, 2020
Page reviewed: July 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external